ClinicalTrials.gg
CompletedNCT04532125ARGX-117Updated Sep 21, 2022

SAD and MAD Study With IV and SC Doses of ARGX-117

A Phase 1 interventional study of ARGX-117 and Placebo in Healthy Volunteers, sponsored by argenx. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-21.

Sponsored by argenx · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a phase 1, first-in-human, double-blinded, randomized, placebo-controlled, escalating single and multiple dose levels trial to evaluate the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of ARGX-117 administered IV and/or SC. Up to 112 healthy, adult male and female subjects of non-childbearing potential will be enrolled in this trial.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject is between 18 to 65 years of age, inclusive, at the time the form (ICF) is signed.
  2. The subject is either male, or female of nonchildbearing potential. Females in the following categories are considered a woman of nonchildbearing potential:

    1. female: A postmenopausal state is defined as continuous amenorrhea for at least 1 year without an alternative medical cause and a follicle-stimulating hormone (FSH) measurement of >40 IU/L. A historical pretreatment FSH measurement of>40 IU/L is accepted as proof of a postmenopausal state for subjects on hormone replacement therapy.
    2. Surgically sterile female: women who have had a documented permanent sterilization procedure (ie, hysterectomy, bilateral salpingectomy, or bilateral oophorectomy).
  3. Female subjects must have a negative serum pregnancy test on day -1 before IMP can be administered.
  4. The subject has a (BMI) within the range 18 to 30 kg/m2 and body weight 50 to 100 kg (inclusive) before IMP administration.
  5. The subject is able to understand the requirements of the study and provide written informed consent (including consent for the use and disclosure of research-related health information), and is willing and able to comply with the study protocol procedures (including the required study visits).
  6. The subject is in good physical and mental health, per the opinion of the investigator, based on medical history; physical examination findings; recordings; vital sign measurements; systemic lupus erythematous (SLE) panel results; and biochemistry, hematology, , and urinalysis laboratory test results prior to the first dose of IMP on day 1.
  7. Nonsterilized male subjects who are sexually active with a female partner of must use effective from the signing of the ICF through 260 days after the last IMP administration. A male subject practicing true sexual abstinence (as consistent with the preferred and usual lifestyle) can be included. Sterilized male subjects who have had a vasectomy and with documented absence of sperm post-procedure can be included. Male subjects are not allowed to donate sperm from signing of the ICF through 260 days after the last dose of IMP.
  8. The subject has abdominal skin that, in the opinion of the investigator, allows for the absorption and localized safety assessment of SC administration (applicable for dose levels with SC administration only).
  9. The subject agrees to discontinue and refrain from the use of all medications, including nonprescription and/or prescription medications, for at least 2 weeks before the first dose of IMP through the EOS visit on day 260 (Part A [SAD]), day 288 (Part B [MAD], cohorts 1 through 5). The occasional use of paracetamol at doses up to 2 g/day with a maximum of 10 g/2 weeks is allowed upon approval from the investigator. COVID-19 immunization recommendations are described in Section 4.3.1.1.
  10. The subject is a nonsmoker and does not use any nicotine-containing products. A nonsmoker is defined as an individual who has abstained from smoking for at least 3 months prior to screening.
  11. The subject has a negative urine drug and alcohol screen for amphetamines, barbiturates, benzodiazepines, cannabis, cocaine, opiates, methadone, tricyclic antidepressants and alcohol at screening and on day -1.
  12. The subject has a body temperature of 35.5 °C to 37.6 °C at screening and prior to the first dose of IMP day 1.

Exclusion criteria

Exclusion criteria:

  1. The subject has a known to any of the components of the IMP, or, in the opinion of the investigator, a history of a significant allergic reaction to any drug.
  2. The subject has previously participated in a clinical study with efgartigimod and was administered an IMP.
  3. The subject has a positive serum test at screening for an active viral infection with any of the following conditions:

    1. virus (HBV) that is indicative of an acute or chronic infection (https://www.cdc.gov/hepatitis/HBV/PDFs/SerologicChartv8.pdf)
    2. virus (HCV) based on HCV antibody assay
  4. The subject tests positively at screening for SLE as determined by the SLE test panel.
  5. The subject has a known family history of SLE.
  6. The subject has known immunological disorders.
  7. The subject has a history of severe allergic or anaphylactic reactions.
  8. The subject has clinical evidence of significant serious diseases, underwent a recent major surgery, or has any other condition that, in the opinion of the investigator, could confound the results of the study or put the subject at undue risk. The conditions and diseases that will lead to subject exclusion include recognized uncontrolled risk factors associated with acute respiratory distress syndrome (ARDS) and death in subjects with COVID-19 (eg, hypertension, diabetes, asthma, or [COPD]).
  9. The subject has a clinically significant uncontrolled active or chronic bacterial, viral, or fungal infection at screening.
  10. The subject has the presence or sequelae of gastrointestinal, liver, kidney, or other conditions known to potentially interfere with the absorption, distribution, metabolism, or excretion of IMP.
  11. The subject has an estimated of \<80 mL/min/1.73 m² (calculated per the Chronic Kidney Disease Epidemiology Collaboration method) at screening.
  12. The subject has a history of except for:

    1. Adequately treated basal cell or squamous cell skin cancer
    2. Carcinoma in situ of the cervix
  13. The subject has known genetic deficiencies for the complement cascade system.
  14. The subject has clinically relevant abnormalities detected on an that are related to either rhythm or conduction (eg, >450 ms for male and QTcF >470 ms for female subjects, or a known long QT syndrome).
  15. The subject has clinically relevant vital sign abnormalities before the first dose of IMP.
  16. The subject had significant blood loss, including blood donation >500 mL, or transfusion of any blood product within 12 weeks before the first dose of IMP, or the subject has a scheduled transfusion within 4 weeks after the end of the study.
  17. The subject has received treatment with any drug known to have a well-defined potential for toxicity to a major organ in the last 3 months before the first dose of IMP.
  18. The subject has a history of any of the following:

    1. consuming more than 21 units of alcoholic beverages per week (Note: 1 unit is 330 mL of beer, 110 mL of wine, or 28 mL of spirits)
    2. alcoholism or drug, chemical, substance abuse within 2 years before screening
    3. consuming a large quantity (>6 cups per day) of coffee, tea, or the equivalent in the 4 weeks before the first dose of IMP.
  19. The subject is concurrently participating or has participated, within 90 days before the first dose of IMP or, if known, 5 half-lives of the drug (whichever is longer), in any drug/device or biologic investigational research study.
  20. The subject has been administered any systemic agent within 6 months prior to the first dose of IMP.
  21. The subject has been administered any systemic within 3 months prior to the first dose of IMP.
  22. The subject is an investigator, subinvestigator, research assistant, pharmacist, study coordinator, or other staff or relative of study personnel directly involved with the conduct of the study.
  23. The subject has any condition or circumstances that, in the opinion of the investigator, may make a subject unlikely or unable to complete the study or comply with study procedures and requirements.
  24. The subject is a pregnant or lactating female, or intends to become pregnant during the study or within 260 days after the last dose of IMP.
  25. The subject has any condition that impairs phlebotomy.
  26. The subject has a positive nasopharyngeal polymerase chain reaction (PCR) test for SARS-CoV-2 on day -2 or -1.
  27. The subject has any contact with anyone who has tested positive for SARS-CoV-2 or COVID-19 within the last 2 weeks prior to admission to the clinical research center.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
110 participants (actual)

Study arms

  • Experimental
    ARGX-117 IV

    Subjects receiving ARGX-117 IV

    Biological: ARGX-117

  • Placebo comparator
    Placebo IV

    Subjects receiving placebo IV

    Other: Placebo

  • Experimental
    ARGX-117 PH20 SC

    Subjects receiving ARGX-117 PH20 SC

    Biological: ARGX-117 PH20 SC

  • Placebo comparator
    Placebo PH20 SC

    Subjects receiving placebo PH20 SC

    Other: Placebo PH20 SC

  • Experimental
    ARGX-117 + rHuPH20

    Subjects receiving ARGX-117 + rHuPH20

    Biological: ARGX-117 + rHuPH20

  • Placebo comparator
    Placebo + rHuPH20

    Subjects receiving placebo + rHuPH20

    Other: placebo + rHuPH20

Interventions

  • BiologicalARGX-117

    Subjects treated with ARGX-117

  • OtherPlacebo

    Subjects treated with placebo

  • BiologicalARGX-117 + rHuPH20

    Drug pages: Empasiprubart · Hyaluronidase (human recombinant)

    Subjects treated with ARGX-117 + rHuPH20

  • Otherplacebo + rHuPH20

    Subjects treated with placebo + rHuPH20

  • Subjects treated with ARGX-117 PH20 SC

  • OtherPlacebo PH20 SC

    Subjects treated with placebo PH20 SC

06

What researchers measure

Primary outcomes

  1. Number of (S)AE

    Time frame: Up to 37 weeks (arm 1) and up to 42 weeks (arm 2)

Secondary outcomes

  1. Area Under The Curve (AUC)

    Time frame: Up to 37 weeks (arm 1) and up to 42 weeks (arm 2)

  2. Maximum serum concentrations (Cmax)

    Maximum observed serum concentration

    Time frame: Up to 37 weeks (arm 1) and up to 42 weeks (arm 2)

  3. Time to reach maximum serum concentrations (Tmax)

    Time calculated to reach Cmax

    Time frame: Up to 37 weeks (arm 1) and up to 42 weeks (arm 2)

  4. Free C2 concentration

    Functional complement activity

    Time frame: Up to 37 weeks (arm 1) and up to 42 weeks (arm 2)

  5. Total C2 concentration

    Functional complement activity

    Time frame: Up to 37 weeks (arm 1) and up to 42 weeks (arm 2)

  6. CH50 titers

    Functional complement activity

    Time frame: Up to 37 weeks (arm 1) and up to 42 weeks (arm 2)

  7. Level of anti-drug antibodies

    Immunogenicity against ARGX-117

    Time frame: Up to 37 weeks (arm 1) and up to 42 weeks (arm 2)

07

Study locations

1 site
  • Investigator Site 1
    Groningen, Netherlands
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Aug 2022, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2020
First posted
Aug 31, 2020
StartActual
Aug 3, 2020
Primary completionActual
Aug 26, 2022
CompletionActual
Aug 26, 2022
Last update
Sep 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04532125
Lead sponsor
argenx
Responsible party
Sponsor
First posted
Aug 31, 2020
Start date
Aug 3, 2020
Primary completion
Aug 26, 2022
Completion
Aug 26, 2022
Last update
Sep 21, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Empasiprubart · Hyaluronidase (human recombinant)

Start the discussion